Novel systems for membrane chromatography
Optimally run membrane chromatography processes will provide higher productivity, smaller-scale operations and increased robustness.
Sartorius Stedim Biotech (SSB) and Novasep France, have entered into a collaboration agreement regarding chromatography and single-use bioprocessing. Novasep provides various products and services to the life science industry, based on specialized technologies. In particular, this company is a recognized system provider with substantial expertise in the design, manufacture and control of resin-based batch and continuous chromatography systems.
Novasep’s established BioSC platform and SSB’s single-use technology will form the basis for the development of innovative chromatography systems. Systems currently on the market are designed for resins, but do not take full advantage of membrane chromatography capabilities. Optimally run membrane chromatography processes will provide the most attractive alternative to batch and continuous resin-based chromatography - namely higher productivity, smaller-scale operations and increased robustness.
Systems designed for membrane chromatography applications are a part of SSB’s global product strategy to supply complete solutions for upstream and downstream processing in life sciences. “Membranes are the embodiment of process intensification. As the market leader in membrane chromatography, SSB aims to realize this potential and offer customers the full benefits of our Sartobind portfolio,” explained Dr Fritjof Linz, Head of Separation at SSB. “We are happy to work with a highly competent partner like Novasep to introduce new membrane chromatography technology for flow through and capture applications,” the Sartorius manager added.
Nadège Laborde, President Process Solutions at Novasep, commented: “This collaboration is a wonderful opportunity for Novasep and SSB, as it leverages the core capabilities of the two companies. The result of this venture will satisfy the latest market demands for continuous processing, process intensification, performance, and ease of use.”
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance